Overview

Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out what effects (good and bad) docetaxel, oxaliplatin, and cetuximab have on gastric or GEJ cancer.
Phase:
Phase 2
Details
Lead Sponsor:
US Oncology Research
Collaborators:
Eli Lilly and Company
ImClone LLC
Sanofi
Treatments:
Cetuximab
Docetaxel
Oxaliplatin